Chakrabarti, Gaurab <br/><br/>
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.  [electronic resource] 

 -  Scientific reports  Nov 2015 
 - 17066 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/srep17066  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Autophagy--drug effects<br/>Catalase--genetics<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>DNA Breaks, Double-Stranded--drug effects<br/>DNA Glycosylases--antagonists & inhibitors<br/>DNA Repair--drug effects<br/>DNA-Binding Proteins--antagonists & inhibitors<br/>Dicumarol--pharmacology<br/>Female<br/>Humans<br/>Hydroxylamines--pharmacology<br/>Mice<br/>Mice, Nude<br/>NAD(P)H Dehydrogenase (Quinone)--antagonists & inhibitors<br/>Naphthoquinones--pharmacology<br/>Pancreatic Neoplasms--drug therapy<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Reactive Oxygen Species--metabolism<br/>Transplantation, Heterologous<br/>X-ray Repair Cross Complementing Protein 1